Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raguneprocel iPSC-derived dopaminergic progenitor cell transplantation in Parkinson's disease (post-marketing study)
jRCT2053260117Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of DSP-1083 in Parkinson's disease (PD) (2 arms), sponsored by Sumitomo Pharma. Started Jul 2026; status: recruiting.
02
Drugs
DSP-1083
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2053260117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053260117.